AR and triple-negative breast carcinoma: Expression of the androgen receptor (AR) in breast cancer is even less studied, although in recent years research on AR expression has been increased for its prognostic value [41,42,43] and as a potential therapeutic target for triple-negative breast cancer [44,45,46,47,48,49,50,51].